Karyopharm Therapeutics Inc. (KPTI)
NASDAQ · Healthcare
Karyopharm Therapeutics Inc. EBITDA 2011–2025
Karyopharm Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2011 to 2020. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Karyopharm Therapeutics Inc. ebitda for the quarter ending March 31, 2020 was -47.1 M, a 27.15% decrease year-over-year.
- Karyopharm Therapeutics Inc. ebitda for the twelve months ending March 31, 2020 was -180.7 M.
- Karyopharm Therapeutics Inc. annual ebitda for 2019 was -188.3 M, a 5.11% increase from 2018.
- Karyopharm Therapeutics Inc. annual ebitda for 2018 was -179.1 M, a 37.99% increase from 2017.
- Karyopharm Therapeutics Inc. annual ebitda for 2017 was -129.8 M, a 18.01% increase from 2016.
- Karyopharm Therapeutics Inc. annual ebitda for 2016 was -110.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Karyopharm Therapeutics Inc. EBITDA — FAQ
Karyopharm Therapeutics Inc. (KPTI) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KPTI's ebitda history?
The chart and table above show Karyopharm Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.